The VE-BASKET study, which treated a wide range of glioma patients with BRAF V600 mutation with BRAF inhibition, showed a PXA case with a complete response (14% of PXA treated, n = 7, and 4% of all gliomas, n = 24), two cases with partial responses (29% of PXA, and 8% of all gliomas), and three cases with stable disease (43% of PXA, and 12.5% of all gliomas). The gene discussed is BRAF; the disease is glioma.